JP6630364B2 - 水溶性プロドラッグ - Google Patents

水溶性プロドラッグ Download PDF

Info

Publication number
JP6630364B2
JP6630364B2 JP2017549601A JP2017549601A JP6630364B2 JP 6630364 B2 JP6630364 B2 JP 6630364B2 JP 2017549601 A JP2017549601 A JP 2017549601A JP 2017549601 A JP2017549601 A JP 2017549601A JP 6630364 B2 JP6630364 B2 JP 6630364B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
bis
substituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017549601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509441A5 (enExample
JP2018509441A (ja
Inventor
坂　仁志
仁志 坂
正児 上岡
正児 上岡
裕介 澤山
裕介 澤山
チャン チア リー，
チャン チア リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JP2018509441A publication Critical patent/JP2018509441A/ja
Publication of JP2018509441A5 publication Critical patent/JP2018509441A5/ja
Application granted granted Critical
Publication of JP6630364B2 publication Critical patent/JP6630364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017549601A 2015-03-27 2016-03-25 水溶性プロドラッグ Expired - Fee Related JP6630364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139077P 2015-03-27 2015-03-27
US62/139,077 2015-03-27
PCT/IB2016/051706 WO2016157052A1 (en) 2015-03-27 2016-03-25 Water-soluble prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019221478A Division JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ

Publications (3)

Publication Number Publication Date
JP2018509441A JP2018509441A (ja) 2018-04-05
JP2018509441A5 JP2018509441A5 (enExample) 2019-02-14
JP6630364B2 true JP6630364B2 (ja) 2020-01-15

Family

ID=55650622

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017549601A Expired - Fee Related JP6630364B2 (ja) 2015-03-27 2016-03-25 水溶性プロドラッグ
JP2019221478A Expired - Fee Related JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ
JP2021081570A Pending JP2021120401A (ja) 2015-03-27 2021-05-13 水溶性プロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019221478A Expired - Fee Related JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ
JP2021081570A Pending JP2021120401A (ja) 2015-03-27 2021-05-13 水溶性プロドラッグ

Country Status (7)

Country Link
US (3) US10183925B2 (enExample)
EP (1) EP3274346A1 (enExample)
JP (3) JP6630364B2 (enExample)
CN (1) CN107660202B (enExample)
CA (1) CA2980845A1 (enExample)
TW (1) TWI710555B (enExample)
WO (1) WO2016157052A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016157052A1 (en) 2015-03-27 2016-10-06 Boston Biomedical, Inc. Water-soluble prodrugs
JP6936214B2 (ja) 2016-03-25 2021-09-15 大日本住友製薬株式会社 ２−アルキルカルボニルナフト［２，３−ｂ］フラン−４，９−ジオンの関連物質の製造方法、及びその関連物質
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US20200207782A1 (en) * 2017-09-22 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd Chemically activated water-soluble prodrug
JPWO2021039616A1 (enExample) * 2019-08-23 2021-03-04
FR3112145A1 (fr) * 2020-07-03 2022-01-07 Nanotracks Diagnostics Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations
WO2022003181A1 (fr) * 2020-07-03 2022-01-06 Nanotracks Diagnostics Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée
CN112194598B (zh) * 2020-10-15 2021-12-21 郑州猫眼农业科技有限公司 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法
EP4431491A4 (en) * 2021-11-08 2025-03-05 Asahi Kasei Kabushiki Kaisha CARBONYL COMPOUND, METHOD FOR PRODUCING A CARBONYL COMPOUND, METHOD FOR PRODUCING AN ISOCYANATE COMPOUND AND ISOCYANATE COMPOSITION
CN118302407A (zh) * 2021-11-08 2024-07-05 旭化成株式会社 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160949T1 (hr) 2007-09-10 2016-10-07 Boston Biomedical, Inc. Novi sastavi i metode za liječenje karcinoma
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
CN104080449A (zh) * 2012-02-17 2014-10-01 舟山海中洲新生药业有限公司 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2016157052A1 (en) * 2015-03-27 2016-10-06 Boston Biomedical, Inc. Water-soluble prodrugs

Also Published As

Publication number Publication date
US10183925B2 (en) 2019-01-22
JP2020055854A (ja) 2020-04-09
JP6885999B2 (ja) 2021-06-16
TW201639824A (zh) 2016-11-16
US20190084955A1 (en) 2019-03-21
HK1243079A1 (zh) 2018-07-06
JP2021120401A (ja) 2021-08-19
JP2018509441A (ja) 2018-04-05
US11414394B2 (en) 2022-08-16
EP3274346A1 (en) 2018-01-31
TWI710555B (zh) 2020-11-21
CA2980845A1 (en) 2016-10-06
WO2016157052A1 (en) 2016-10-06
CN107660202A (zh) 2018-02-02
US20180111914A1 (en) 2018-04-26
US10800752B2 (en) 2020-10-13
US20200392098A1 (en) 2020-12-17
CN107660202B (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
JP6630364B2 (ja) 水溶性プロドラッグ
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
AU2019356565B2 (en) Prodrug modulators of the integrated stress pathway
TWI804003B (zh) Tlr7/8拮抗劑及其用途
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
EP3041822B1 (en) Compounds useful as immunomodulators
ES2588680T3 (es) Compuestos de tiazolopirimidina
JP2023065588A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
JP6619420B2 (ja) Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
WO2021172359A1 (ja) Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
HK1243079B (zh) 水溶性前药
KR20250117821A (ko) Hdac 억제제 및 이의 용도
JP2005023007A (ja) 複素環化合物およびその用途
BR122021006373B1 (pt) Antagonistas de tlr7/8 policíclicos, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191206

R150 Certificate of patent or registration of utility model

Ref document number: 6630364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees